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Pancreatic cancer is a highly lethal malignancy with a dismal 5-year survival of less than 5%. The scarcity of early biomarkers has
considerably hindered our ability to launch preventive measures for this malignancy in a timely manner. Neutrophil gelatinase-
associated lipocalin (NGAL), a 24-kDa glycoprotein, was reported to be upregulated nearly 27-fold in pancreatic cancer cells
compared to normal ductal cells in a microarray analysis. Given the need for biomarkers in the early diagnosis of pancreatic cancer,
we investigated the expression of NGAL in tissues with the objective of examining if NGAL immunostaining could be used to identify
foci of pancreatic intraepithelial neoplasia, premalignant lesions preceding invasive cancer. To examine a possible correlation between
NGAL expression and the degree of differentiation, we also analysed NGAL levels in pancreatic cancer cell lines with varying grades
of differentiation. Although NGAL expression was strongly upregulated in pancreatic cancer, and moderately in pancreatitis, only a
weak expression could be detected in the healthy pancreas. The average composite score for adenocarcinoma (4.26±2.44) was
significantly higher than that for the normal pancreas (1.0) or pancreatitis (1.0) (Po0.0001). Further, although both well- and
moderately differentiated pancreatic cancer were positive for NGAL, poorly differentiated adenocarcinoma was uniformly negative.
Importantly, NGAL expression was detected as early as the PanIN-1 stage, suggesting that it could be a marker of the earliest
premalignant changes in the pancreas. Further, we examined NGAL levels in serum samples. Serum NGAL levels were above the
cutoff for healthy individuals in 94% of pancreatic cancer and 62.5% each of acute and chronic pancreatitis samples. However, the
difference between NGAL levels in pancreatitis and pancreatic cancer was not significant. A ROC curve analysis revealed that ELISA
for NGAL is fairly accurate in distinguishing pancreatic cancer from non-cancer cases (area under curve¼0.75). In conclusion, NGAL
is highly expressed in early dysplastic lesions in the pancreas, suggesting a possible role as an early diagnostic marker for pancreatic
cancer. Further, serum NGAL measurement could be investigated as a possible biomarker in pancreatitis and pancreatic
adenocarcinoma.
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Pancreatic adenocarcinoma is one of the most aggressive cancers,
with an estimated 37000 new cases and 34000 deaths in 2007 in the
United States alone (Jemal et al, 2007). The poor prognosis is to a
large extent due to the fact that only 15–20% of pancreatic
adenocarcinoma cases are resectable, and a mere 5% of patients
survive 5 years (Cleary et al, 2004). The current treatment
modalities for this malignancy, surgery, radiation, and chemo-
therapy, alone or in combination, have done little to improve the
grim outlook; and once metastasis has set in, death is almost
certain (Li et al, 2004). Nevertheless, an understanding of the
pathogenesis of pancreatic adenocarcinoma, along with the
development of new treatment methods and diagnostic techniques
aimed at early detection, may facilitate effective prevention, and
increase survival rates among patients.
Using microarray analysis, many laboratories have reported the
differential expression of several novel genes associated with the
progression of pancreatic cancer (Argani et al, 2001; Han et al,
2002; Terris et al, 2002). Of these genes, we chose to focus our
interest on NGAL (neutrophil gelatinase-associated lipocalin),
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swhich is known to be overexpressed in pancreatic cancer
(Han et al, 2002).
Neutrophil gelatinase-associated lipocalin is also known
variously as NRL (neu-related lipocalin), oncogene 24p3,
uterocalin, and lipocalin 2 (LCN2). It is a 24-kDa glycoprotein
stored in specific granules of human neutrophils (Cowland and
Borregaard, 1997). It belongs to the lipocalin family that comprises
more than 50 known members, all of which are characterised by
their low molecular weight and their ability to bind to and
transport small lipophilic substances (Bratt, 2000; Xu and Venge,
2000). Although its structure is known, the specific functions of
NGAL are yet to be elucidated. It is expressed during the transit of
granulocytes in the bone marrow, which suggests a possible role
for it in granulocyte maturation (Borregaard et al, 1995). More
recently, NGAL has been shown to participate in iron trafficking
(Yang et al, 2003) and proposed to participate in the iron depletion
strategy used by the innate immune system against bacterial
pathogens (Goetz et al, 2002). By regulating the delivery of iron
into cells, it has been demonstrated to regulate iron-responsive
genes that are important in the differentiation of primordial cells
(Mori et al, 2003). Further, upregulation of NGAL in haemato-
poietic stem cells subjected to IL-3 starvation has been shown to
promote apoptosis (Jayaraman et al, 2005). Thus, NGAL has a
multifaceted role in several key cellular functions.
The deregulated expression of NGAL has been reported in
several benign and malignant conditions. Neutrophil gelatinase-
associated lipocalin expression was significantly upregulated in
ovarian cancer tissues with borderline and grade I tumours
showing the highest expression (Lim et al, 2007). Its expression
was also increased in oesophageal dysplasia and squamous cell
carcinoma, suggesting that it could be a marker of early dysplastic
change (Zhang et al, 2007). Neutrophil gelatinase-associated
lipocalin–matrix metalloproteinase-9 (MMP-9) complexes were
identified in nearly 84% of urine sample from breast cancer
patients while being absent from matched control samples
(Fernandez et al, 2005). Neutrophil gelatinase-associated lipocalin
was also identified as an independent indicator of poor prognosis
in these patients (Bauer et al, 2007). Thus, NGAL appears to be a
marker of dysplasia and thus could be useful to identify such
changes in high-risk patients.
The idea of a possible link between NGAL and pancreatic cancer
was first presented by Furutani et al (1998), who identified NGAL
as one of the genes significantly overexpressed in pancreatic
cancer cell lines. This observation was confirmed by Argani et al
(2001). Three molecules, TFF2 (trefoil factor 2), PSCA (prostate
stem cell antigen), and NGAL, were scored very highly in tumours
compared to the normal pancreas. Finally, in 2002, two
independent groups highlighted the possible role of NGAL in
pancreatic cancer. The first group comprising Han et al (2002)
used high-density cDNA microarray performed on neoplastic vs
normal pancreatic cells and observed a 27-fold upregulation of
NGAL in three pancreatic cancer cell lines compared to the normal
pancreas. Following this, Terris et al (2002) identified NGAL in a
search for markers of IPMN (intraductal papillary mucinous
neoplasm), a precursor lesion known to lead to invasive
carcinoma. More recently, Iacobuzio-Donahue et al (2003a,b),
exploring the global gene expression pattern in pancreatic
adenocarcinoma using cDNA microarrays, reported a significant
overexpression of NGAL in pancreatic cancer. However, the
association of NGAL expression with the progression of pancreatic
cancer and the possible role of plasma/serum NGAL levels as a
diagnostic/prognostic marker in this lethal malignancy has not yet
been explored.
Our laboratory is working for the past decade in trying to
uncover the molecular and cellular mechanisms that drive the
tumorogenic and metastatic potential of pancreatic cancer cells.
Given the reported overexpression of NGAL in pancreatic cancer
cell lines and its possible role in tumour cell differentiation,
apoptosis, and inflammation, we explored the hypothesis that
NGAL plays an important role in the early stages of pancreatic
cancer pathogenesis and that its detection could potentially be
useful in the diagnosis of pancreatic cancer. The expression of
NGAL in pancreatic intraepithelial neoplasia (PanIN) lesions
of various grades and in foci of pancreatitis adjacent to the areas
of adenocarcinoma was examined by immunohistochemistry. We
also examined NGAL transcript and protein expression in
pancreatic cancer cell lines with varying degrees of differentiation
to evaluate if NGAL expression correlates with epithelial
differentiation. Further, we analysed NGAL levels in serum of
patients with pancreatic cancer to investigate whether serum
NGAL could be used to distinguish patients with pancreatic cancer
from those with pancreatitis or disease-free pancreas.
MATERIALS AND METHODS
Tissue samples and cell lines
Eight pancreatic tissue samples from healthy donors, 1 from acute,
3 from chronic pancreatitis, and 27 from PDAC (pancreatic ductal
adenocarcinoma) patients were collected after prior consent and
fixed in formalin. In addition, 2 normal pancreatic tissue samples
from healthy donors, 8 chronic pancreatitis, and 14 pancreatic
adenocarcinoma samples were obtained at the time of primary
surgery after obtaining appropriate consent and snap-frozen in the
liquid nitrogen for RNA analysis. Samples were collected under a
protocol approved by the Institutional Review Board at the
University of Nebraska Medical Center (Andrianifahanana et al,
2001). Thirteen pancreatic adenocarcinoma cell lines with different
levels of differentiation (poorly, moderately, and well differen-
tiated) (Sipos et al, 2003) were examined: MiaPaCa, Panc1, Panc89,
QGP1, S2CP9, AsPC1, BxPC3, Capan1, HPAF, HPAC, Colo357,
Hs766T, and SW1990.
Blood samples and isolation of serum
Blood samples were obtained from in-patients at the University of
Nebraska Medical Center (UNMC, Omaha, NE, USA) under a
research protocol approved by the local institutional review board
(IRB’s 209-00-EP). Whole blood was transferred from an
anticoagulant citrate dextrose solution formula A-capped tube
(ACD-A) to a conical tube (Nalgene, Rochester, NY, USA). Samples
were centrifuged for 10min at 1000g in a swing bucket rotor at
41C, and the serum was stored in cryovials at  801C.
Immunohistochemistry
Paraffin sections were deparaffinised in xylene, followed by
rehydration in graded ethanol and treated for 20min with 0.3%.
H2O2/methanol to block endogenous peroxidase. Epitope retrieval
was performed by microwaving the slides in 0.01 M citrate buffer
(pH 6.0). The sections were blocked with normal goat serum for
1h, followed by incubation with rabbit anti-NGAL pAb (1:1000
dilution) overnight at 41C. The slides were then washed with PBS-T
(3 5min) before incubation with secondary antibody for 30min.
Slides were washed again (3 5min) with PBS-T before incubating
with the ABC solution. The reaction colour was developed by
incubating the sections with DAB reagent. The slides were washed
with distilled water, counterstained with haematoxylin, and
dehydrated and mounted with Permount permanent mounting
media (Fisher Scientific, Fair Lawn, NJ, USA).
All slides were observed under a Nikon Light Microscope and
representative photographs taken. The intensity of immuno-
reactivity of NGAL was scored. The staining intensity was graded
on a scale of 0 to 3þ (0 for no staining, 1þ for weak
immunoreactivity; 2þ for moderate immunoreactivity; and
3þ for strong immunoreactivity). The percentage of cells that
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sshowed positive NGAL staining within the normal/cancerous
region of a section was scored as follows: (1) 0–25% of cells
positive; (2) 26–50%; (3) 51–75%; and (4) 76–100% cells positive
for NGAL immunostaining. The staining intensity score and the
percent immunoreactivity score were then multiplied to obtain
a composite score. The values of the composite score ranged from
a minimum of 0 to a maximum of 12. The Mann–Whitney U-test
was used to compare the composite score among the groups
(normal pancreas/pancreatitis/pancreatic adenocarcinoma). No
multivariate analysis was carried out owing to the moderate
number of events. Differences between the groups were defined as
being statistically significant if the P-value was less than 0.05.
RNA isolation and reverse transcription–PCR analysis
Total RNA from tissue samples and cell lines was isolated by
guanidine isothiocyanate cesium chloride ultracentrifugation
method. A total of 2mg RNA was reverse-transcribed using the
SuperScriptt II RNase-Reverse Transcriptase System (Invitrogen,
Carlsbad, CA, USA). The cDNA was then subjected to PCR with
1.5mM magnesium chloride, 2.5U Taq polymerase (Fermentas,
Hanover, MD, USA) in a total volume of 50ml and specific primers
for NGAL/LCN2. After 3min initial denaturation at 941C, 30 cycles
of amplification (45s 941C, 45s 601C, 60s 721C) were performed.
RPL13A was used as an internal control. The PCR products were
electrophoretically resolved on 1% agarose gels stained with
ethidium bromide. Photographs were taken under UV light, using
the GelExpert software system (Nucleotech, San Mateo, CA, USA).
The sequence of the forward primer for NGAL is 50-TTC
CTCGGCCCTGAATCATG-30 and that of reverse primer is 50-CTG
GCGGCACCTGTGCACTCA-30. RPL13A primers used were those
reported previously (Andrianifahanana et al, 2001).
Cell lysates and Western blot
Cells were lysed in modified RIPA buffer (50mM Tris-HCl, pH 7.4;
0.25% Na-deoxycholate; 150mM NaCl; 1% NP-40; 1mM EDTA),
supplemented with 1mgml
 1 aprotinin, 1mgml
 1 leupeptin,
5m M NaF, 5mM Na3VO4, and 1mM phenylmethylsulphonyl
fluoride. Total cellular protein was extracted on ice for 30min
and further cleared by centrifugation at 16000g for 10min. The
supernatant (comprising the protein extracts) was collected and
stored at  801C until further use.
The total protein was electrophoretically fractionated on 15%
Laemmli SDS–polyacrylamide gels and electroblotted onto PVDF
membranes. Blotted membranes were blocked in 5% BSA and
subsequently exposed to primary antibodies specific for NGAL,
diluted (1:1000) in PBS. The rabbit polyclonal anti-NGAL
antibody, generously provided by Dr Gould (University of
Wisconsin, Madison, WI), was raised against recombinant NGAL
protein (Stoesz et al, 1998). After incubation with the appropriate
secondary antibody, the membranes were treated with ECL reagent
(Amersham Biosciences, Piscataway, NJ, USA) and exposed to
autoradiographic films. The membranes were then stripped and
re-probed with antibodies specific for b-actin.
Determination of serum NGAL levels by sandwich ELISA
The concentration of NGAL in the serum of patients was
determined by using the NGAL Rapid ELISA Kit (Antibody Shop,
Gentofte, Denmark). Serum from patients with acute or chronic
pancreatitis (n¼8 in each group) and pancreatic cancer (n¼16)
were tested. Serum from healthy donors (n¼8) were chosen as the
control. Each sample was diluted 100-fold using the sample
diluent provided with the kit. A volume of 50ml horseradish
peroxidase-conjugated detection antibody was added to each well
of a 96-well plate precoated with NGAL antibody. Thereafter, 50ml
each of the calibrator (provided by the manufacturer), sample
(pancreatitis, pancreatic cancer, or healthy control serum sample),
or sample diluent alone (blank) was rapidly added to the
corresponding wells. After incubating at room temperature for
30min with agitation (200min
 1), the contents of the microwell
were aspirated and replaced with 100ml of the chromogenic
peroxidase substrate tetramethylbenzidene (TMB). The plate was
incubated for 15min in the dark, the reaction stopped by adding a
‘stop solution’, and the absorbance read at 450nm with a
microplate reader.
RESULTS
Immunohistochemistry of pancreatic tumours
To investigate the association between NGAL expression and
pancreatic cancer pathogenesis, the NGAL expression pattern in
the pancreas was investigated either by immunohistochemistry or
RT–PCR. Immunohistochemistry experiments were performed on
39 formalin-fixed tissue samples representing normal (n¼8),
pancreatitis (n¼4), and pancreatic adenocarcinoma (n¼27),
using the rabbit anti-NGAL polyclonal antibody (Stoesz et al,
1998). The results are summarised in the Tables 1–3. In the eight
sections of normal pancreas investigated, a weak NGAL staining
was detected, restricted to the small ducts (Figure 1). A weak
staining was also detected in some medium size ducts (average
composite score: 1). The staining appeared cytoplasmic for the
small ducts, and luminal for the larger ducts. In addition, a
subpopulation of cells within the islets also appeared positive for
NGAL (1–2 cells per islet). One acute and three chronic
pancreatitis tissue sections were also examined. Neutrophil
gelatinase-associated lipocalin antibody moderately labeled the
small and medium size ducts (average composite score: 1), and in
one case of chronic pancreatitis, the centroacinar cells (Figure 1).
Thus, a weak and restrictive pattern of NGAL expression was
observed in all non-malignant cells.
All the 27 pancreatic adenocarcinoma tissue sections were
positive for NGAL expression, although with a heterogeneous
pattern of staining (Table 3). Most (80–90%) of the medium and
larger sized ducts were labeled with the antibody. However, a range
of staining patterns was observed in the foci of pancreatitis and
PanIN surrounding the adenocarcinoma areas. Although the foci
of pancreatitis directly surrounding the cancer were strongly
positive for NGAL (Figure 1), a strong staining was noted in all the
PanIN lesions (Table 2), with an intense staining observable as
early as PanIN-1 (Figure 1). Pancreatic intraepithelial neoplasia-1
lesions had an average composite score of 11.4, PanIN-2 of 11.25,
and the PanIN-3 of 9.88 (Table 2). There was a statistically
significance difference (Po0.004.) between the three grades of
PanIN lesions (Po0.004). In well-established adenocarcinoma,
Table 1 Immunohistochemical assessment of NGAL expression in
pancreatitis and PDAC
Tissue specimen N Average composite score
Normal pancreas 8 1±0
Pancreatitis 4 1±0
Adenocarcinoma 27 4.26±2.44
a
N¼specimen number; NGAL¼neutrophil gelatinase-associated lipocalin; PDAC¼
pancreatic ductal adenocarcinoma. The staining intensity was graded on a scale of
0–3 (0¼no staining, 1¼weak, 2¼moderate, and 3¼strong staining). The
percentage of cells that were positive for NGAL were scored as follows:
1¼o25% cells positive, 2¼25–50% cells positive, 3¼50–75% cells positive,
and 4¼75–100% cells positive. The staining intensity score and percent positivity
score for each section were multiplied to obtain a composite score for that section.
The composite score ranged from 0 to 12.
aThe difference in the staining score
between normal and adenocarcinoma of the pancreas was statistically significant:
Po0.0001.
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in some cases, negative. The intensity of the staining and the
number of positive cells were directly associated with the degree of
differentiation, with well-differentiated cancer staining more than
the poorly differentiated areas (Figure 1). The mean composite
score was 4.23 for well-differentiated pancreatic adenocarcinoma
and 3.33 for the moderately differentiated pancreatic adenocarci-
noma (Table 3). All the poorly differentiated adenocarcinomas
were uniformly negative. The normal pancreas adjacent to the
malignant area presented a labeling pattern identical to that
observed in the normal pancreas of healthy individuals with
immunostaining restricted to the small ducts. A few strongly
positive cells were also observed in the islets, localised to within
the close proximity of the tumour tissue. A significant difference
was observed in NGAL expression (as measured by the composite
score) between the normal and cancerous areas (Po0.0001). Thus,
whereas sections of the normal pancreas and pancreatitis (in the
absence of associated malignancy) expressed NGAL weakly, high
levels of expression were noted in the areas of PanIN, with
comparable levels in foci of pancreatitis surrounding the cancer.
Neutrophil gelatinase-associated lipocalin staining in invasive
adenocarcinoma, however, directly varied with the degree of
differentiation with well differentiated the most intense and poorly
differentiated the least.
RT–PCR of tissues and cell lines
Having examined NGAL expression in tissues, we then investigated
the variation at the transcript level both in tissues and cell lines.
An RT–PCR analysis of pancreatic tissue samples (2 normal
pancreas, 8 pancreatitis, and 14 pancreatic cancer) revealed a faint
amplification product (confirmed as NGAL after sequencing) in
Table 2 NGAL expression in pancreatic intraepithelial neoplasia by immunohistochemistry
PanIN
PanIN-1 PanIN-2 PanIN-3
N
a Average composite score N Average composite score N Average composite score
20 11.4±1.23 16 11.25±1.34 17 9.88±1.44
b
NGAL¼neutrophil gelatinase-associated lipocalin; PanIN¼pancreatic intraepithelial neoplasia. NGAL expression in the PanIN lesions adjacent to the areas of pancreatic cancer
was calculated. The average composite score for PanIN lesions of a given grade was then calculated.
aN represents the number of tissue specimens containing PanIN lesions of a
given grade.
bThe difference in the composite score between PanIN-1, -2, and -3 stages was statistically significant: Po0.004.
Table 3 NGAL staining by immunohistochemistry in PC tissue sections
Well-differentiated Moderately differentiated Poorly differentiated
Sample number
% positive cells
(intensity of the
staining)
Composite
score
% positive cells
(intensity of the
staining)
Composite
score
% positive cells
(intensity of the
staining)
Composite
score
1 25 (2) 2
2 75 (3) 9
3 25 (1) 1 75 (0) 0
4 75 (2) 6
5 25 (2) 2 75 (0) 0
6 25 (2) 2 75 (0) 0
7 25 (2) 2
8 50 (3) 6
9 50 (3) 6 25 (2) 2
10 25 (3) 3 50 (2) 4
11 25 (3) 3
12 50 (2) 4
13 25 (1) 1
14 25 (3) 3 75 (0) 0
15 75 (3) 9 25 (0) 0
16 50 (3) 6
17 50 (3) 6
18 50 (3) 6
19 25 (3) 3 75 (0) 0
20 25 (3) 3 75 (0) 0
21 25 (3) 3 75 (0) 0
22 25 (3) 3 50 (2) 4
23 25 (3) 3 25 (3) 3 50 (0) 0
24 25 (2) 2 75 (0) 0
25 25 (3) 3 75 (0) 0
26 25 (3) 3
27 25 (2) 2
Mean composite
score
4.23±2.12 3.3±20
NGAL¼neutrophil gelatinase-associated lipocalin; PC¼pancreatic cancer. A total of 27 PC tissue sections were investigated for NGAL expression by immunohistochemistry.
The table presents the distribution of the composite scores in well-differentiated vs moderately and poorly differentiated cancer areas. The columns on the extreme right and at
the bottom of the table represent the total composite score for a given PC section and the mean composite score for a given grade of differentiation, respectively. The scores
were calculated as described in Table 1.
NGAL and pancreatic cancer diagnosis
N Moniaux et al
1543
British Journal of Cancer (2008) 98(9), 1540–1547 & 2008 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sthe normal tissues, a moderate-to-strong band in pancreatitis, and
a strong amplification product in all pancreatic cancer samples
(Figure 2). Neutrophil gelatinase-associated lipocalin expression
was also investigated in pancreatic cancer cell lines by either RT–
PCR (data not shown) or Western blot. Western blot revealed
a high level of expression of the 24kDa NGAL protein in all the
well-differentiated pancreatic cancer cell lines (S2CP9, Colo357,
HPAF, and HPAC), weak expression in the moderately differ-
entiated pancreatic cancer cell lines (Capan-1, SW1990, HS766T,
ASPC-1, and Panc89), and no detectable expression in the poorly
differentiated pancreatic cancer cell lines (Panc1, MiaPaCa, BxPC3,
and HCG25) (Figure 3). The rabbit polyclonal antibody against
b-actin JLA20 (Sigma-Aldrich, St Louis, MO, USA) was used to
control the equity in sample loading. Pancreatic ductal cancer cell
lines are classified as well, moderately, or poorly differentiated
according to their ultrastructural features, including the integrity
of membrane-bound structures, presence of mucin granules,
cell organelles, nuclear and cellular polymorphism, cell polarity,
and lumen formation (Sipos et al, 2003). These results suggest a
differential overexpression of NGAL in well- and moderately
differentiated pancreatic cancer cell lines, thereby suggesting
a potential association between NGAL expression and the
differentiation of pancreatic cancer cells.
Normal 
adjacent tumour
Pancreatitis
adjacent tumour PanIN-1 PanIN-3 PanIN-2
Invasive 
adenocarcinoma
Acute 
pancreatitis Normal
Well-differentiated 
adenocarcinoma
Moderately 
differentiated 
adenocarcinoma
Poorly 
differentiated 
adenocarcinoma
Pancreatic cancer progression
Figure 1 A representative immunohistochemical analysis of NGAL during the pathogenesis of the pancreatic gland. Representative sections of formalin-
fixed, paraffin-embedded tissues immunolabelled with polyclonal anti-NGAL antibody using the horseradish peroxidase detection method with DAB
substrate. Brown-coloured product indicates positive immunoreactivity. (A) Neutrophil gelatinase-associated lipocalin expression in normal pancreas, acute
pancreatitis, and well-, moderately, and poorly differentiated pancreatic adenocarcinoma. The normal and pancreatitis tissue samples presented a weak
staining in the small and small/medium size ducts, respectively. For pancreatic adenocarcinoma, a gradient of NGAL expression was detected from strongest
in well-differentiated tumours to absent staining in poorly differentiated tumours. (B) Correlation of NGAL expression with pancreatic cancer progression.
Neutrophil gelatinase-associated lipocalin positivity was identified in the premalignant PanIN lesions as early as PanIN-1. Pancreatitis surrounding the
cancer stained as strongly as the PanIN areas. The staining intensity was weaker in the well-differentiated adenocarcinoma (top panel: original magnification
 10 and bottom panel: original magnification  20). All sections were counterstained with haematoxylin.
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- P8
NGAL
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Figure 2 Neutrophil gelatinase-associated lipocalin transcript expression
in normal, pancreatitis, and pancreatic cancer tissues. Neutrophil gelatinase-
associated lipocalin expression was investigated by RT–PCR on 2 normal
pancreas (N1 and N2), 8 chronic pancreatitis (P1–P8), and 14 pancreatic
cancer tissue samples (T1–T14), respectively. RPL13A expression was
used as an internal reference.
NGAL
HPAF
MiaPaCa
Panc1
Panc89
QGP1
S2CP9
AsPC1
BxPC3
Capan1
HPAC
Colo357
HS766T
SW1990
HCG25
β-Actin
Figure 3 Western blot analysis of NGAL in a panel of pancreatic cancer
cell lines. Protein lysates from 14 pancreatic cancer cell lines were resolved
on a 15% SDS–PAGE gel and transferred to a PVDF membrane. After
blocking with 5% BSA, the blot was hybridised with anti-NGAL antibodies
(upper panel), stripped and re-probed with anti-b-actin (lower panel) to
demonstrate loading of proteins in all lanes.
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From the preceding experiments, we observed that NGAL was
overexpressed in pancreatic adenocarcinoma, but very weakly in
normal and pancreatitis tissues. Hence, to examine if quantitative
analysis of NGAL levels in blood could distinguish pancreatic
cancer from pancreatitis, we analysed serum samples for NGAL
levels. Using an established cutoff for healthy individuals
(106ngml
 1), serum NGAL levels in 94% of the pancreatic cancer
samples. A total of 62.5% of the acute and chronic pancreatitis
serum samples each also had NGAL levels above the upper limit
for normal. The mean and median NGAL levels are listed
in Table 4. Further, the serum levels of NGAL in normal
vs pancreatitis (acute/chronic) and pancreatic cancer samples
were analysed by non-parametric tests (Table 5). The Kruskal–
Wallis test showed a significant difference (Po0.002) in the
distribution of serum NGAL levels across the groups (normal,
acute/chronic pancreatitis, and pancreatic cancer). However, when
a pair-wise comparison was performed using the Wilcoxon test, we
observed that although serum NGAL levels were significantly
higher in acute (P¼0.035), chronic pancreatitis (P¼0.035), and
pancreatic cancer (P¼0.004) compared to healthy controls, there
was no significant difference between the pancreatitis and
pancreatic cancer samples (P¼1.000). This suggested that NGAL
levels in the serum were elevated both in inflammatory and
neoplastic pathologies of the pancreas. We also analysed the ability
of the serum NGAL assay to distinguish pancreatic cancer from
non-cancer cases by fitting the data to a simple logistic regression
model where samples were categorised as ‘cancer’ or ‘no-cancer’,
and mean NGAL was used as the predictor. The analysis revealed
that serum NGAL levels in cancer were not significantly different
from non-cancer cases (comprising normal and pancreatitis cases)
to be diagnostically useful (P¼0.101). However, a ROC curve
analysis revealed that the area under the curve was 0.75 (Figure 4),
which indicates that the test is fairly accurate in classifying cases as
‘cancer’ or ‘no-cancer’. Taken together, the results suggest that
although the measurement of serum NGAL alone may not provide
diagnostic accuracy in distinguishing pancreatic cancer patients
from those with pancreatitis, it warrants further exploration as a
diagnostic marker for pancreatic cancer in combination with other
markers. Further, similar to its elevation in the early stages of acute
renal injury, NGAL could be explored as an early marker of
pancreatic damage in acute pancreatitis.
DISCUSSION
NGAL is the human homologue of the murine molecule known as
oncogene 24p3 (mouse) and neu/HER2-related lipocalin (rat).
Oncogene 24p3 was first identified as being overexpressed in
oncogene-mediated cell transformation (Hraba-Renevey et al,
1989). The protein was named NGAL because it was observed to
form a complex with the gelatinase MMP9 (Kjeldsen et al, 1993).
Neutrophil gelatinase-associated lipocalin is a multifunctional
protein and is released from activated neutrophils (Elneihoum
et al, 1996) and thought to act as a bacteriostatic agent (Goetz et al,
2002). Additionally, it also appears to be important in cellular
differentiation being highly expressed in fetal hypertrophic
chondrocytes, developing skeletal muscle fibers, and during
myocardial development. The expression of NGAL is highest just
before the onset of cellular differentiation (Zerega et al, 2000).
Therefore, it is suggested that NGAL favours differentiation of
primordial cells.
The observation that induction of NGAL correlates with
apoptosis led to the hypothesis that NGAL is a pro-apoptotic
factor (Huang et al, 1999; Ryon et al, 2002). This hypothesis was
furthered strengthened by the observation that NGAL induced the
apoptosis of neutrophils through an autocrine pathway (Devireddy
et al, 2001). In a recent publication, Tong et al (2005) showed that
although NGAL expression is closely associated with apoptosis, it
also favours cell survival. Thus, NGAL appears to have a complex
functional role.
Neutrophil gelatinase-associated lipocalin has been reported to
be overexpressed in pancreatic cancer cell lines and tissues
(Furutani et al, 1998; Argani et al, 2001; Han et al, 2002). However,
its role in the early stages of pancreatic cancer pathogenesis
Table 4 Descriptive statistics of NGAL levels in serum
Group Diagnosis N
a
Mean
(ngml
 1)
Median
(ngml
 1)
I Normal 8 44.19 43.43
II Chronic pancreatitis 8 166.64 125.43
III Acute pancreatitis 8 123.38 122.23
IV Pancreatic cancer 16 151.65 143.75
NGAL¼neutrophil gelatinase-associated lipocalin. Serum NGAL levels were
determined by a sandwich ELISA method. Mean and median NGAL levels were
calculated for each of the four groups.
aN refers to the number of samples in a given
group.
Table 5 Assessment of discriminative ability of the serum NGAL ELISA
assay to distinguish normal patients from pancreatitis or pancreatic
adenocarcinoma cases
Comparison P-value
a
Pancreatic cancer vs normal 0.0042
Pancreatic cancer vs chronic pancreatitis 1.0000
Pancreatic cancer vs acute pancreatitis 1.0000
Chronic pancreatitis vs normal 0.0354
Acute pancreatitis vs normal 0.0354
Chronic pancreatitis vs ncute pancreatitis 1.0000
NGAL¼neutrophil gelatinase-associated lipocalin. Differences in serum NGAL levels
between the four groups (outlined in Table 4) were analysed by the Wilcoxon test.
The Bonferroni correction for multiple comparisons was applied to the data. A
difference in mean serum NGAL level between any two groups was considered
significant if the P-valueo0.05.
aP-values for pair-wise comparisons are from the
Wilcoxon test. These P-values were adjusted using the Bonferroni adjustment for
multiple comparisons.
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Figure 4 Receiver operating characteristic (ROC) curve analysis of
diagnostic sensitivity and specificity of the plasma NGAL ELISA assay. The
performance of plasma NGAL measurement assay in discriminating
patients with pancreatic cancer from those without cancer (normal, acute,
and chronic pancreatitis) was evaluated. The area under the curve (AUC)
was 0.75, suggesting that the test is fairly accurate in distinguishing the two
groups.
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and differential expression pattern for NGAL in pancreatic adeno-
carcinoma compared to that in the normal. Neutrophil gelatinase-
associated lipocalin expression was low in the normal pancreas
and in pancreatitis, but very high in the early dysplastic lesions
(PanINs), being detectable as early as PanIN-1; it has been
previously explored as a marker of premalignant lesions in ovarian
cancer (Lim et al, 2007). The intense staining noted in the early
PanIN lesions suggests that NGAL could be a marker of early
dysplasia in the pancreas. Pancreatic intraepithelial neoplasia
lesions have been reported to be present in the ducts of
histologically normal pancreatic tissue (Andea et al, 2003; Gupta
and Mazzara, 2005; Pan and Wang, 2007), including a progressive
increase in their frequency from normal pancreas through
pancreatitis to pancreatic cancer (16, 60, and 82%, respectively)
(Andea et al, 2003). This has been proposed as evidence to support
the role of these lesions as harbingers of ductal adenocarcinoma.
However, in our study, we did not observe any PanIN lesions in the
sections of normal pancreas, possibly attributable to the small
number of normal tissues examined. In the areas of adenocarci-
noma itself, NGAL expression correlated positively with the
grade of differentiation (moderate expression for the highly
differentiated vs negative for the poorly differentiated cancer).
As the degree of differentiation of pancreatic cancer correlates
inversely with its aggressiveness, hence detection of NGAL in
tissue sections appears to be a good marker of the early, less
belligerent stages of this malignancy.
The early diagnosis of pancreatic cancer is difficult owing to the
late presentation of symptoms. A study comparing various
diagnostic tests used in pancreatic cancer revealed that imaging
techniques are the most sensitive method to identify patients
suspected to have pancreatic cancer (Go et al, 1981). However,
most patients in this study had unresectable tumours when first
identified. Hence, a marker to identify early stage cancer or high-
grade dysplasia would be immensely useful to improve survival.
Neutrophil gelatinase-associated lipocalin being upregulated in the
earliest stage of pancreatic intraepithelial neoplasia could be useful
as a marker of dysplasia in high-risk patients (e.g. long-standing
chronic pancreatitis and hereditary pancreatitis). However, it is
unlikely by itself to be sufficiently sensitive to detect all cases. Its
performance in combination with other potential early diagnostic
markers needs to further exploration.
Serum NGAL measurement has been shown in studies to be
elevated early in acute renal injury (Mishra et al, 2005; Dent et al,
2007) and in patients with borderline tumours of the ovary (Lim
et al, 2007). Having established the differential overexpression in
pancreatic cancer, specifically in the PanIN lesions, we next
investigated whether the measurement of NGAL levels in the
serum could be useful to distinguish pancreatic cancer from non-
cancer cases (including, pancreatitis). Although serum NGAL
levels were significantly elevated both in inflammation (pancrea-
titis) and malignancy of the gland, there was no significant
difference between the serum levels in pancreatitis vs that in
pancreatic cancer. This suggests that serum NGAL level alone is
inadequate in distinguishing pancreatic cancer from chronic or
acute pancreatitis. The role of NGAL as a mediator of inflamma-
tion has been reported previously following the nearly 55-fold
increase in the mucosal release of NGAL in patients with colitis
and proctitis (Carlson et al, 2002). Studies examining the effect of
cytokines on hepatocytes showed that IL-b but not IL-6 induced
the release of NGAL, suggesting a differential regulation of NGAL
secretion by inflammatory cytokines (Jayaraman et al, 2005). It has
been suggested that the upregulation of NGAL in liver cells in
response to cytokines is a negative feedback mechanism to counter
the effects of IL-1b-induced inflammation. Analogously, NGAL
overexpression could serve to counter tumour-induced inflamma-
tory response in pancreatic cancer (Jayaraman et al, 2005). The
NGAL serum ELISA test appears to be fairly accurate in
distinguishing pancreatic cancer from non-pancreatic cancer cases
(area under the ROC curve¼0.75). This raises the possibility that
it might be useful in the diagnosis of pancreatic cancer in
combination with other, more specific markers. Further, its
significantly high levels in both acute and chronic pancreatitis
suggested that serum NGAL levels could also be explored as a
possible diagnostic marker in pancreatitis in the appropriate
clinical context.
In the tumour microenvironment, one of the earliest changes
that precedes the onset of a metastatic phenotype is an epithelial–
mesenchymal transition associated with loss of E-cadherin
expression, morphologic changes, and an increase in cellular
motility (for review see Thiery, 2003a,b). Hanai et al (2005)
recently showed that NGAL has the ability to reverse this
epithelial-mesenchymal transition, thereby diminishing invasive-
ness of cancer cells. Our results show that in pancreatic cancer,
NGAL is predominantly expressed in the early dysplastic lesions as
well as in the well-differentiated carcinomas (preserve ductal
architecture); with almost no expression in the poorly differen-
tiated tumours (have a predominantly mesenchymal appearance).
These results led us to hypothesise that loss of NGAL expression
drives the progression of pancreatic ductal carcinoma from a well
to poorly differentiated tumour. Further experiments will need to
be performed to prove this hypothesis. However if true, the
development of recombinant NGAL-based therapies might slow
down this epithelial-to-mesenchymal transformation and thereby
the progression of this lethal cancer.
Pancreatic cells, either ductal, islet, or acinar, have the property
to transdifferentiate into any other pancreatic cell type. Neutrophil
gelatinase-associated lipocalin might initiate this process in the
pancreatic cells. The identification of the factor(s) that induce(s)
NGAL overexpression in PanIN lesions as early as PanIN-1A is
essential to understand the mechanisms underlying the initiation
and regulation of pancreatic ductal cell transformation, and
transdifferentiation. A control over transdifferentiation of pan-
creatic cells might provide a new therapeutic approach for
pancreatic cancer and possibly a cure for diabetes mellitus.
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